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Abstract: Diabetic neuropathy (DN) is a debilitating disorder occurring in most diabetic patients 
without a viable treatment yet. The present work examined the protective effect of 25Mg-PMC16 
nanoparticle (porphyrin adducts of cyclohexil fullerene-C60) in a rat model of streptozotocin 
(STZ)-induced DN. 25Mg-PMC16 (0.5 lethal dose50 [LD50]) was administered intravenously in two 
consecutive days before intraperitoneal injection of STZ (45 mg/kg). 24Mg-PMC16 and MgCl2 were 
used as controls. Blood 2,3-diphosphoglycerate (2,3-DPG), oxidative stress biomarkers, adenosine 
triphosphate (ATP) level in dorsal root ganglion (DRG) neurons were determined as biomarkers 
of DN. Results indicated that 2,3-DPG and ATP decreased whereas oxidative stress increased by 
induction of DN which all were improved in 25Mg-PMC16-treated animals. No significant changes 
were observed by administration of 24Mg-PMC16 or MgCl2 in DN rats. It is concluded that in DN, 
oxidative stress initiates injuries to DRG neurons that finally results in death of neurons whereas 
administration of 25Mg-PMC16 by release of Mg and increasing ATP acts protectively.
Keywords: diabetes, neuropathy, 25Mg-magnetic isotope effect, porphyrin-fullerene nanopar-
ticles, oxidative stress, adenosine triphosphate, nanotechnology
Introduction
The number of people with diabetes is developing due to population growth, aging, and 
increasing prevalence of obesity and physical inactivity. The total number of people 
with diabetes is estimated to rise from 171 million in 2000 to 366 million in 2030.1 
Diabetic neuropathy (DN) usually develops in about 4%–10% of diabetic patients after 
five years and in 15% after 20 years.2 It is estimated that at least 50% of all diabetic 
patients will suffer from neuropathy in their lifetime.3
Hyperglycemia in diabetes causes an overflow of the polyol pathway, advanced 
glycation, oxidative stress, and deficiencies in neurotrophic factors. On the other 
hand, hypoinsulinemia results in mitochondrial dysfunction. Unfortunately, to date, 
a viable treatment for human DN is not available and all current drugs like tricyclic 
antidepressants, anticonvulsant agents, aldose reductase inhibitors, and drugs such as 
Υ-linolenic acid, zenarestat, mexiletine and midodrine are only used for management.5 
Oxidative stress is established to have a fundamental role in development of DN 
through induction of mitochondrial dysfunction, decline of adenosine triphosphate 
(ATP), and neural death. 2,3-diphosphoglycerate (2,3-DPG) as one of the factors 
contributing to tissue hypoxia is decreased in DN. Reduced levels of 2,3-DPG in 
DN result in a defect in delivery of oxygen to dorsal root ganglion (DRG) neurons 
leading to hypoxia and neuron death. It is believed that any rise in ATP and 2,3-DPG 
improve oxygenation.4–6International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Recently, nanoparticles of a magnetic isotope of magnesium 
(25Mg-PMC16) has been developed with low toxicity and 
membranotropic antioxidant effect. This nanoparticle, which 
possesses marked cationite properties, is the iron containing 
  porphyrin monoadduct of a classical buckminster fullerene 
named ‘‘Porphylleren-MC16’’ or, in brief, PMC16. 25Mg isotopes 
that are released by this nanoparticle   activate both substrate 
and oxidative phosphorylation pathways in acidosis condition 
and stimulate production of ATP in oxygen-  depleted cells.7,8 
  Positive antiapoptotic and antioxidant effects of Mg, fullerene, 
and porphyrin that exist within structure of this nanoparticle 
have been previously known.9–12
Regarding accumulation potential of this nanoparticle in 
the neuronal mitochondria,7 and the pathophysiology of DN, 
the hypothesis of this study was that 25MgPMC16 by reduc-
tion of oxidative stress and increasing ATP in DRG neurons 
would protect mitochondrial dysfunction in DN. Therefore, 
the possible effects of  25Mg-PMC16 in an experimental 
model of DN were examined in comparison to nonmagnetic 
24Mg-PMC16 and the ordinary form of Mg (MgCl2).
Methods
Materials
Adenosine diphosphate (ADP) sodium salt, ATP disodium 
salt, Tris base, 1,1,3,3-tetraethoxypropane (MDA), 5,5′-
dithiobis-2-nitro benzoic acid (DTNB), methanol (high 
performance liquid chromatography [HPLC]-grade), trichlo-
roacetic acid (TCA), potassium hydroxide, MgCl2, diethyl 
ether, ketamine, xylazin, tetrabutylammonium hydroxide 
(TBAHS), n-butanol, 2-thiobarbituric acid (TBA), KH2PO4 
(analytical grade), and 2,4,6-tripyridyl-s-triazine (TPTZ) 
from Merck (Tehran), streptozotocine (STZ) from Phar-
macia and Upjohn (USA),  25Mg-PMC16 and  24Mg-PMC16 
from Semenov institute (Russian Academy of Sciences), 
A SUPELCOSIL™ LC-18-T HPLC column from SUPELCO 
(UK) and 2,3-DPG determination kit from Roche (Germany) 
were used in this study.
Treatment
Male Wistar rats weighing 200 ± 5 g were randomly divided 
in five groups with six rats in each group containing the con-
trol group that received nothing, DN group which received 
a single intraperitoneal (ip) injection of STZ (45 mg/kg), 
the protective group with 25Mg-PMC16 received two intra-
venous (iv) injections of  25Mg-PMC16 (0.5 lethal dose50 
[LD50] = 448 mg/kg) with 48 hours interval before receiving 
STZ by ip injection, the protective groups with 24Mg-PMC16 
and MgCl2 received two iv injections of 24Mg-PMC16 and 
MgCl2 (0.5 LD50= 448 and 88 mg/kg, respectively) with 
two days   intervals followed by a single ip injection of STZ. 
Different doses of the nanoparticle according to its LD50 
and literature were selected and tested. At first, the work 
was started with 0.2 LD50 according to previous study (7), 
but no suitable response was received. Then the dose was 
increased to 0.5 LD50 and the proper effects were observed 
in all experiments.
In vivo studies were carried out according to ethical 
guidelines on the use of animals in research and the protocol 
was approved by institute review board.
Induction of DN
Experimental diabetes was induced by ip injection of dis-
solved STZ in normal saline with pH of 7 at the dose of 
45 mg/kg. Before an injection of STZ, animals were fasted 
for 12 hours. Within one week of injection, animals became 
hyperglycemic, with raised blood glucose between 250 mg/dl 
and 500 mg/dl that resulted in DN after two months.13
Measurement of blood glucose  
and weight
Blood glucose and weight of animals at the beginning of 
study and after two months were measured using a gluco-
meter and a special balance.
sample preparation
Sample preparation included blood, plasma, and tissues. 
At first, animals were anesthetized with intramuscular (im) 
injection of ketamine (4 mg/100 g) and xylazine (1 mg/100 g) 
mixture, then the abdomen was opened and blood (5 ml) was 
collected from the heart into a heparinized syringe. Collected 
blood samples were centrifuged at 1200 g for 10 min at 4°C 
and plasma frozen at −80°C until further analysis. For tissue 
preparation, after anesthetizing the animals, the spinal cord 
and paraspinal tissue from the second cervical to the second 
lumbar vertebra were removed altogether. Then the cervical 
spine laminae were removed until the spinal ganglia were 
exposed. The sixth cervical (C6) DRG on each side was 
removed and frozen quickly in liquid nitrogen.
Measurement of 2,3-DPG
This measurement was carried out using a kit. Since 2,3-DPG 
is too labile, the deproteinization procedure had to be 
  performed immediately using perchloric acid (0.6 M) and 
potassium carbonate solution (2.5 M). 2,3-DPG is stable 
for at least one day in the neutralized extracts and thus the 
samples were tested within 24 hours. 2,3-DPG is split by International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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the side activity of phosphoglycerate mutase (PGM) to form 
phosphoglycerate (PG). Both, 2-PG and 3-PG can be formed. 
2-PG is isomerized into 3-PG. 3-PG is converted by phos-
phoglycerate kinase (PGK), glyceraldehyde-3-phosphate 
dehydrogenase (GAP-DH), triosephosphate isomerase 
(TIM) and glycerol-3-phosphate dehydrogenase (GDH). 
Meanwhile, 2 mole of nicotinamide adenine dinucleotide 
(NADH) is oxidized per mole of 2,3-DPG. Then absorption 
of NADH was determined at 340 nm.14
Measurement of total plasma  
antioxidant capacity
The ability of plasma to reduce Fe3+ to Fe2+ is an   indicator 
of plasma antioxidant capacity. The complex between 
Fe2+ and 2,4,6-tris(2-pyridyl)-1,3,5-triazine(TPTZ) gives 
a blue color with absorbance at 593 nm that is read by 
spectrophotometer.15
Measurement of plasma total thiol groups
Total sulfhydryl level was determined as described previous-
ly.16 A plasma volume of 0.2 ml was mixed with 0.6 ml of Tris 
– EDTA buffer [Tris base (0.25 M), EDTA (20 mM), pH 8.2] 
in a 10 ml test tube and then mixed with 40 ml of DTNB (10 
mM) in methanol. The final volume was made up to 4.0 ml 
by adding 3.16 ml of methanol. The test tube, after capping, 
centrifuged at 3000 g for 10 min at ambient temperature. 
After 15–20 min, the color appeared. The absorbance of the 
supernatant was measured at 412 nm.16
Measurement of lipid peroxidation (LPO)
LPO of plasma was measured by the reaction of TBA with 
MDA and other lipid peroxides. Plasma samples were mixed 
with TCA (20%) and the produced precipitate was dispersed 
in H2SO4 (0.05 M). After addition of TBA (0.2% in sodium 
sulfate) the samples were heated for 30 minutes in a boiling 
water bath. Then LPO adducts were extracted by n-butanol 
and absorbance was read at 532 nm.17
Measurement of adenosine diphosphate 
(ADP) and ATP
The frozen DRG was removed on ice and was quickly homog-
enized (4°C) in 1 mL of ice-cold 6% TCA. The homogenate 
was centrifuged at 12000 g for 10 min at 4°C. The supernatant 
was neutralized to a pH of 6.5 with 4 M KOH. Then it was 
filtered through a millipore filter (pore size 0.45 µm), and the 
neutralized extract was used to determine the concentrations 
of ATP and ADP (µg/mL per mg of tissue) using ion pair-high 
performance liquid chromatography (  IP-HPLC). Standard 
solutions of ATP and ADP were used to get a standard curve 
and then samples were tested to express energy changes as 
an ADP/ATP ratio.18
statistical analysis
All values were expressed as a mean ± standard error (SE). 
Data was statistically analyzed by analysis of variance 
(ANOVA) followed by Newman–Keuls using Stat Direct 
version 2.7.7. P-Values less than 0.05 were considered sta-
tistically significant.
Results
Animal’s weight and blood glucose
Weights of DN rats significantly reduced as compared with 
control rats (P , 0.001). Blood glucose in DN rats signifi-
cantly increased as compared to control rats (P , 0.001). 
After use of  25MgPMC16, a significant increase in ani-
mal weight and decrease in glucose level were observed 
(P , 0.01 and P , 0.05, respectively) when compared to 
DN rats. No significant changes were observed by use of 
24Mg-PMC16 and MgCl2 (Figures 1 and 2).
Blood 2,3-DPG
There was a significant decrease in 2,3-DPG concentration 
in DN group (P , 0.001) as compared to control rats but 
administration of 25Mg-PMC16 caused a significant increase 
of this marker (P , 0.001). No significant changes were 
observed by administration of  24Mg-PMC16 and MgCl2 in 
DN rats (Figure 3).
Biomarkers of oxidative stress
A significant decrease in total antioxidant capacity and total 
thiol molecules (P , 0.01 and P , 0.05, respectively) and 
an increase of LPO (P , 0.001) in DN group were recorded 
in comparison to controls. Administration of 25Mg-PMC16 
increased total antioxidant capacity and total thiol molecules 
(P , 0.01 and P , 0.001, respectively) and decreased LPO 
(P , 0.01) as compared to DN group. No significant changes 
were detected by administration of 24Mg-PMC16 and MgCl2 
(Table 1).
ATP and ADP in Drg neurons
As observed in Figure 4, a significant increase in ADP/ATP 
ratio in DN rats is evident in comparison to the control group 
(P , 0.001). The administration of 25Mg-PMC16 reduced the 
ADP/ATP ratio in comparison to the DN group (P , 0.001). 
24Mg-PMC16 and MgCl2 caused no significant changes.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 Protective effects of various forms of magnesium on blood glucose in DN rats after two months.
Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P , 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant 
at P , 0.05(b).
Abbreviations: DN, diabetic neuropathy; se, standard error.
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Figure 2 Protective effects of various forms of magnesium on weight of DN rats after two months.
Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P , 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant 
at P , 0.05(bb).
Abbreviations: DN, diabetic neuropathy; se, standard error.
Discussion
The present findings indicate a significant improvement in 
biomarkers of DN including blood 2,3-DPG and oxidative 
stress, DRG neuronal ADP/ATP by use of 25Mg-PMC16. 
Interestingly no considerable improvement was found in DN 
when 24Mg-PMC16 or MgCl2 were used.
The unique structure of 25Mg-PMC16 as a nanocationite 
helps smart release of Mg into DN cells that are in hypoxic 
acidosis condition and imbalance of oxidative phospho-
rylation and ATP. Meanwhile, the porphyrin domain of 
PMC16 provides a tissue selective interaction for porphyrin 
  receptors located in the mitochondrial membrane. It seems 
that water-soluble C60-fullerene derivatives have the ability 
to selectively accumulate inside mammalian mitochondria.7 
This nanoparticle is safe for use, because the hepatic turnover 
of PMC16 occurs mainly on the porphyrin domain that forms 
biologically neutral heme precursor. The hepatic metabolites 
include alanyl-depleted PMC16 (54.6% of total metabolites 
amount), deacetylated PMC16 derivatives (27.0%) and cyclo-
hexyl C60-fullerene (16.2%). In hypoxia, PMC16 becomes 
more resistant to hepatic metabolism.7 Therefore, besides 
Mg, these metabolites themselves may have useful effects 
in DN.
As found in the present study, 2,3-DPG is one of the fac-
tors contributing to tissue hypoxia significantly decreased 
in DN. During glycolysis, metabolism can be diverted into 
the Rapoport–Luebering shunt, generating 2,3-DPG instead 
of ATP. 2,3-DPG binds to deoxyhemoglobin to modulate oxy-
gen affinity and unloading of oxygen at the capillaries. It is 
believed that, reduced levels 2,3-DPG in DN result in a defect International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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in   oxygen delivery within DRG neurons and followed by 
hypoxia and neuron death.19,20 As far as we know, 2,3-DPG 
and ATP decrease the affinity of the hemoglobin for oxygen 
and a close inverse correlation was found between the oxygen 
binding and the concentration of these phospho compounds in 
intact human erythrocytes. ATP and 2,3-DPG have approxi-
mately equal effect on hemoglobin oxygenation. However, 
binding of both phospho compounds decreased at higher 
hydrogen ion concentrations in DN because of hypoxia and 
followed acidosis.21 Thus it seems that 25Mg-PMC16 increases 
2,3-DPG level via three mechanisms. First of all, the increased 
ATP by 25Mg-PMC16 in hypoxic condition and reduced 2,3-
DPG in DN, bind to hemoglobin compensational in the way to 
deliver oxygen to DRG neurons. Second of all, in oxygenated 
erythrocytes that contain a relatively high concentration of 
Mg, it is estimated that almost all of the Mg is bound to ATP 
and with somehow lesser affinity to 2,3-DPG.22 Therefore it 
seems that, deoxygenated erythrocytes in DN, causes com-
plex of Mg and 2,3-DPG to be dissociated easier than that of 
Mg and ATP due to increased ATP and Mg by 25Mg-PMC16 
and high affinity of Mg to ATP. Thus, this leads to increased 
2,3-DPG concentration. Finally, in the process of 2,3-DPG 
production in erythrocytes (Rapoport–Luebering shunt), 
1,3-diphosphoglyceric acid is converted to 3-phosphoglyceric 
acid by phosphoglycerate kinase (PGK) and then to 2,3-DPG 
by a kinase in the presence of ATP.23 Therefore, 25Mg-PMC16 
with improving PGK enzyme activity24 and ATP level proceeds 
the pathway to increase 2,3-DPG in DN.
The present findings also showed a significant increase 
in oxidative stress biomarkers in DN that is supported by 
previous studies. DRG neurons have large mitochondria with 
high oxidative metabolism making them much susceptible to 
oxidative injury. The chronic distal sensory deficits that are 
seen in chronic DN might be more closely related to DRG 
neurons because the blood-nerve and perineurial barriers are 
minor at this site.25 Increased ADP/ATP ratio in DRG neu-
rons in DN group is considered as a marker of mitochondrial 
dysfunction in neurons. Mitochondrial dysfunction itself is a 
central mediator of neural apoptosis in the peripheral nervous 
system and a critical modulator of diabetic neuropathy.4 In 
diabetes, reactive oxygen species (ROS) that are coupled with 
depolarization of the inner mitochondrial membrane (∆ΨMt) 
are associated with an increase in the ADP/ATP ratio and an 
absolute decrease in ATP levels. Also increased metabolic 
flux in the mitochondria due to high glucose is coupled with 
reduction of NAD to NADH that results in further formation 
of ROS. Accumulation of NADH coupled with failure of 
mitochondrial creatine phosphate pump in regeneration of 
2
,
3
-
D
P
G
 
(
m
M
/
m
l
 
e
r
y
t
h
r
o
c
y
t
e
) 0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
Control
DN
25 Mg-PMC 16
24 Mg-PMC 16
MgC1 2
Control
DN
25Mg-PMC16
24Mg-PMC16
MgC12 aaa
aaa
aaa
bbb
Figure 3 Protective effects of various forms of magnesium on 2,3-DPG concentration in erythrocytes of DN rats after two months.
Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P , 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant 
at P , 0.001(bbb).
Abbreviations: DN, diabetic neuropathy; se, standard error.
Table 1 Protective effects of various forms of magnesium on oxidative stress biomarkers
Control DN 25Mg-PMC16
24Mg-PMC16 MgCl2
Total antioxidant capacity 
(µmol/mL)
566.2 ± 46.44 325.7 ± 32.9aa 540.7 ± 39.82bb 344.3 ± 33.89aa 370.5 ± 40.60a
Lipid peroxidation (nmol/mL) 1.73 ± 0.18 5.17 ± 0.45aaa 2.54 ± 0.47bb 4.85 ± 0.53aa 4.8 ± 0.55aa
Total thiol groups (mmol/L) 0.53 ± 0.05 0.26 ± 0.06a 0.47 ± 0.04bbb 0.28 ± 0.04a 0.28 ± 0.03a
Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P , 0.001(aaa), P , 0.01(aa), P , 0.05(a). Difference between DN and 
25Mg-PMC16 is significant at P , 0.001(bbb), P , 0.01(bb).
Abbreviations: DN, diabetic neuropathy; se, standard error.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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ATP from ADP disrupts electron transfer chain and therefore 
results in DRG neuron death.26
Decreased 2,3-DPG and hypoxia and further acidosis in 
DN conditions activates 25Mg-PMC16 and therefore positive 
effects of magnetic Mg is guaranteed.7 There is evidence that 
fullerenes that exist in structure of 25Mg-PMC16 have antioxi-
dant and anti-apoptotic effects due to their potential to react 
with ROS.9 Other studies have shown that both lipophilic 
and hydrophilic C60 derivatives have wonderful potential as 
medicines for treating LPO-related diseases.27–29 Apoptosis is 
a programmed cell death that is mainly due to the change in 
growth factor. In this condition, ROS are released, thus, thera-
pies targeted against ROS are greatly useful for minimizing cel-
lular damage in oxidative stress-mediated neurodegeneration 
and other ROS-dependent disorders.30,31 Fullerene derivatives 
have also anti-apoptotic activity and can prevent apoptosis by 
neutralization of tumor growth factor (TGF)-induced ROS, 
reduction of tumor necrosis   factor (TNF) or ultraviolet-trig-
gered activation of caspases. In addition, fullerene derivatives 
associate with mitochondria more efficiently than conventional 
antioxidants.9,32 On the other hand,  25Mg-PMC16 by releas-
ing Mg in DN hypoxic conditions induces antioxidant and 
anti-apoptotic effects. It has been shown that Mg has a dose-
dependent neuroprotective effect after a spinal cord injury 
that is mediated by reduction of neuronal LPO.11 Also it was 
found that MgSO4 decreases neuron apoptosis after cerebral 
ischemia-reperfusion injury through suppression of caspase-3 
and bax expression.12 Another study showed that MgSO4 sig-
nificantly inhibits endotoxin-induced up-regulation of inflam-
matory molecules and NF-κß activation.33 Mg has been also 
found effective in human poisoning with organophosphates 
that act through inhibition of   cholinesterase and induction of 
  oxidative stress.34 Considering the study indicated a decrease 
in body Mg concentration in diabetes type 1 patients,35 it is 
not surprising to conclude that any elevation of intraneuronal 
Mg is a helpful strategy in the management of DN. Of course 
it should not be forgotten that we saw positive effects only for 
25Mg-PMC16 and not for other forms like 24Mg-PMC16 and 
MgCl2 that were tested in the present study. Thus, the first idea 
that comes to mind is the problem that might exist in reaching 
and accumulating of adequate Mg into neurons. In the plasma 
with normal pH of 7.4, 25Mg-PMC16 cannot easily release Mg 
but hypoxic condition in DN when inside the cells will change 
to acidic pH, then 25Mg-PMC16 will be able to release Mg so 
easily resulting in a dramatical increase of Mg inside DRG 
cells. On the other hand since equal doses of these three forms 
of Mg has been tested, thus one can conclude that magnetic Mg 
plays the effective role much better than other forms of Mg. 
Taking collectively, the present finding confirms that 25Mg-
PMC16 protects from STZ-induced DN through reduction of 
oxidative stress and improving ATP by better reaching neuronal 
cells and release of Mg. Of course positive role of fullerene 
structure of 25Mg-PMC16 cannot be ignored.
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